BRIEF: CANbridge raises $26 million in share sale to WuXi Bio at 14.7% discount
Rare disease drugmaker CANbridge Pharmaceuticals Inc. (1228.HK) announced on Monday that it will sell 84.03 million new shares to WuXi Biologics HealthCare Venture, a subsidiary of WuXi Biologics (2269.HK), for…
